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Abstract
The indications of nutrition support in cancer patients have been subject to controversy. Most
studies address the effects of the method in increasing the survival or the tumor response rate.
Few studies have focused on the effects in improving quality of life.
After a brief review, we described the results of a study, which evaluated the effects of protein-
caloric supplementation on the quality of life parameters in a group of head and neck cancer
patients submitted to radiotherapy. The results support the suggestion of creating standard criteria
to indicate nutrition support in cancer patients.
Based on our findings, nutrition support should be indicated for cancer patients considering the
potential effects to improve the quality of life.
Background
Several studies have been published to evaluate the indi-
cations of nutritional support in cancer. The majority of
these studies are review articles and meta-analysis. A con-
sensus has been sought from the data analyses in order to
establish a standard for nutritional support in cancer.
However, the term "nutritional support" has been applied
almost exclusively for the use of total parenteral nutrition,
instead of the entire modalities of nutrition intervention,
including nutritional supplementation and enteral nutri-
tion. Moreover, several methodological errors have been
shown, which has produced certain controversy in the
data interpretation. Despite the inconsistencies observed,
the general indications of nutrition support in cancer have
resulted in guidelines and recommendations published in
the medical literature. Three reviews were recently pub-
lished addressing this issue.
In the first [1], the authors have reviewed 28 prospective
randomized and controlled clinical trials evaluating the
use of parenteral nutrition in cancer patients. The authors
have concluded that parenteral nutrition can be used in
the pre-operative period in patients having cancer of the
gastrointestinal tract and it is beneficial in the reduction of
major surgical complications and surgical mortality. On
the other hand, no statistically significant benefit could be
demonstrated in survival rate, treatment tolerance, treat-
ment toxicity, and treatment response from patients sub-
mitted to chemotherapy and radiation therapy. Indeed,
there was an increase of the risk of infection in patients
submitted to chemotherapy and receiving parenteral nu-
trition, underscoring the importance of demonstrating
significant benefits in randomized trials before parenteral
nutrition is used routinely in these patients. Twenty-two
of these studies were reported in full paper form and 6 as
abstracts only. The quality of reporting was poor, with
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only 46% of applicable items being reported between the
surgery, chemotherapy, or radiotherapy trials. Based on
the adopted criteria for data evaluating, the review has
showed the following characteristics:
1) 73% of the studies showed eligibility criteria, 41% in-
dicated the source of patients, and 77% gave the patient
characteristics;
2) The treatment plan was often clearly defined in 86% of
the trials, but only 36% gave details of the therapy actually
received;
3) Although the study objectives were described adequate-
ly in 77% of the studies, only 14% clearly described the
method of randomization;
4) No study described the use of a second party review or
even an internal review of the data. Information on cen-
sored data was reported only in 38% of the studies;
5) Basic statistical methods were reported in 64% of the
studies, but an in-depth description was reported in only
27% of the studies;
6) Prognostic factors were used in analyzing the study re-
sults in 36%, but this usually involved a subgroup analysis
only, and
7) The statistical power was discussed only in 1 of the 22
trials.
In addition, the authors stated that the review:
a) Does not rule out a possible positive effect of parenteral
nutrition in cancer patients submitted to chemotherapy
and radiotherapy;
b) Has identified a small sample size in individual studies
and the inability to group the data related to the end
points, resulting in a high probability of not detecting a
therapeutic effect, and
c) Has showed that patients severely malnourished were
excluded from several studies, therefore reducing signifi-
cantly the chances to identify the potential effect of
parenteral nutrition in those patients with significant
weight loss or unable to maintain an adequate nutritional
intake.
The second review is a Position Paper from the American
College of Physicians [2]. A total of 12 randomized and
controlled trials were evaluated to estimate the effects of
parenteral nutrition on survival and tumor response rates
in patients undergoing chemotherapy. The end points
were efficacy and effectiveness of the method and safety,
which result in recommendations known as CEAP State-
ment (Clinical Efficacy Assessment Project Statement).
The CEAP evaluates and informs College members and
others about the safety and efficacy of diagnostic and ther-
apeutic modalities and medical practices. The CEAP state-
ments represent a synthesis of the literature and expert
opinion and are intended to reflect the current state-of-
the-art knowledge concerning technology and medical
practice. The results of the pool analysis have shown that
parenteral nutrition did not improve the tumor response
rate and patients receiving parenteral nutrition were 81%
as likely to survive as control patients. For short-term sur-
vival (3 months), the best estimate of the odds ratio was
0.74, (with 95% confidence limits ranging from 0.42 to
1.3). The effect of parenteral nutrition on chemotherapy
toxicity also was assessed. In the studies reviewed, the use
of parenteral nutrition was associated with four times the
increased risk of significant infection. The pooled odds ra-
tio was 4.1, with 95% confidence limits of 2.4 to 6.9. Al-
though the recognition of considerable heterogeneity of
patients, neoplasms, and circumstances of parenteral nu-
trition administration in the reviewed trials, and the re-
duced global number of patients, the formal statements
and recommendations were:
- The routine use of parenteral nutrition for patients un-
dergoing chemotherapy should be strongly discouraged;
- As most of patients in the studies reviewed were not se-
verely malnourished, the net effect of parenteral nutrition
in these patients is unknown, and
- Clinical trials with subgroups of patients or modifica-
tions of parenteral nutrition can only be justified if such
research provides valid arguments that the effect of
parenteral nutrition support will be different than that ob-
served to date.
The third review is the American Society for Parenteral
and Enteral Nutrition (ASPEN)'s Guidelines for the Use of
Parenteral and Enteral Nutrition in Adult and Pediatric
Patients [3]. It is recommending the following practice
guidelines:
- Enteral tube feeding and parenteral nutrition support
may benefit some severely malnourished cancer patients
or those in whom gastrointestinal or other toxicities are
anticipated to preclude adequate oral nutritional intake
for more than 1 week. Patients who are candidates for nu-
trition intervention under these circumstances should re-
ceive nutrition support, if possible, in conjunction with
the initiation of oncologic therapy;Nutrition Journal 2002, 1 http://www.nutritionj.com/content/1/1/1
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- Specialized nutrition support is not routinely indicated
for well-nourished or mildly malnourished patients un-
dergoing surgery, chemotherapy, or radiation treatment
and in whom adequate oral intake is anticipated, and
- TPN is unlikely to benefit patients with advanced cancer
whose malignancy is documented as unresponsive to
chemotherapy or radiation therapy.
For the studies analyzed in the reviews, the conclusion
drawn was correct: TPN was not beneficial. However,
many people misinterpreted the conclusions without un-
derstanding the nuances of the issues being considered.
This led, in turn, to erroneous assumptions about appro-
priate nutrition management in cancer patients in general
[4].
More recently, studies have been published suggesting the
need to consider quality of life (QoL) as end point in can-
cer trials [5–8]. The studies evaluating efficacy and effec-
tiveness are taking into account the tumor response rate,
survival, and QoL assessment as well. The use of QoL
questionnaires has significantly modified the methodo-
logical procedure in cancer clinical trials. Therefore, the
indication criteria for nutrition support must also incor-
porate the QoL assessment.
Klein and Koretz [9] brought first the idea that QoL assess-
ment should be present in clinical trials involving nutri-
tion support in cancer patients. The authors reviewed 70
prospective randomized controlled trials of nutrition sup-
port in more than 4000 cancer patients and they found
the same results as previously described. However, the au-
thors highlighted the following shortcomings associated
with the reviewed studies:
- The statistical power of most studies was poor because of
small sample size and most trials were unlikely to demon-
strate a therapeutic effect of parenteral nutrition even if
parenteral nutrition was efficacious;
- The patient population enrolled in the studies was heter-
ogeneous consisting of patients with different tumor types
and stages of disease;
- The composition of nutrients, timing of nutrition inter-
vention, and duration of nutrition therapy differed
among studies, making it difficult to pool data and to
evaluate the efficacy of the method;
- Specific cancer therapy varied among studies, therefore
increasing the possibility of confounding the conclusions
made after grouping studies together;
- The patient populations were not stratified in accordance
with their nutritional status, and in many trials the pa-
tients were not limited to those who might benefit most
from nutrition support, that is, those with severe weight
loss;
Table 1: Quality of life scores for each group
EORTC QLQ C-30 SPCe Controlf
A1 A2 A3 A1 A2 A3
P h y s i c a l  f u n c t i o n i n g 5 46 08 25 65 45 1
Emotional functioning 62 70 78 64 64 70
F a t i g u e 5 65 85 45 86 47 2
Pain 42 40 40 46 50 58
Appetite loss 34 32 32 32 40 52
Global health status 62 66 76 60 54 52
aThe questionnaire is composed of both multi-item scale and single item measures that range in score from 0 to 100. 
bA high scale score represents a higher response level for physical functioning and emotional functioning. 
cA high score for the global health status represents high QoL. 
dA high score for fatigue, pain, and appetite loss represents a high level of symptoms. 
eStatistically significant results in PCS group pre-treatment period vs. post-treatment period (p < 0.05). 
fStatistically significant results in PCS group vs. control group at the post-treatment period (p < 0.05) SPC – protein-caloric supplemented group. 
A1 : one week before radiotherapy. 
A2 : 30 days after the beginning of radiotherapy. 
A3 : 60 days after the beginning of radiotherapy.Nutrition Journal 2002, 1 http://www.nutritionj.com/content/1/1/1
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- The quality of reporting most studies was poor;
- Quality of life and other additional endpoints were rare-
ly evaluated.
In which extension nutrition support can improve QoL in
cancer patients, even knowing that the traditional end
points will not be substantially modified? The use of QoL
questionnaires developed to best evaluate QoL in cancer
patients has addressed this issue [10–16].
Methods
In a study published elsewhere [17], our group prospec-
tively compared the QoL effects of nutrition support in
one hundred-forty-six patients with head and neck cancer
submitted to radiotherapy receiving protein-caloric sup-
plementation in routine basis (PCS). Briefly, protein-ca-
loric supplementation in a routine basis (PCS) was
administered to 72 patients (PCS group). The supplemen-
tation consisted of a polymeric formula containing 794
cal and 6,72 g N2, which was daily supplemented with the
regular supervised diet beginning seven days before radio-
therapy continuing seven days after the last day of treat-
ment. The control group (n = 74) received nutritional
counseling and supervised diet with no nutritional sup-
plementation. The QoL was evaluated using the European
Organization for Research and Treatment of Cancer Qual-
ity of Life Questionnaire (EORTC QLQ C-30) in three in-
stances: one week before radiotherapy (A1), 30 days (A2)
and 60 days (A3) after the beginning of therapy. This tool
is composed of both multi-item scale and single item
measures that range in score from 0 to 100. A high scale
score represents a higher response level. A high score for a
functional scale (physical functioning, and emotional
functioning) represents a high/healthy level of function-
ing, high score for the global health status represents high
QoL, and high score for a symptom scale (fatigue, pain,
and appetite loss) represents a high level of symptomatol-
ogy/problems [18]. Statistical analysis was performed us-
ing the t-test for paired samples and the Student t-test.
Results and Discussion
The PCS group had high scores in physical functioning
and emotional functioning and low scores in the scale of
appetite loss. In contrast, the control group showed a per-
sistent low score in physical functioning and a high score
in the symptom scale such as fatigue, pain and appetite
loss. In the analysis of global health status, the PCS group
showed a high score and the control group showed a low
score. Statistically significant results are shown in Table 1.
The results have showed that protein-caloric supplemen-
tation in a routine basis improved the QoL in head and
neck cancer patients submitted to radiotherapy and
should be considered as a useful supportive practice.
Moreover, these findings support the idea that studies re-
lated to the effects of nutrition support in cancer should
incorporate the QoL assessment as a primary endpoint.
Conclusions
Based on the results of QoL evaluation in cancer patients,
the indications of nutrition support should be expanded
and reviewed. The criteria to prescribe nutrition support
have to take into account the following aspects:
1) Related to the effectiveness of the anti-neoplastic ther-
apy:
- Stage I – Curative, that is, the anti-neoplastic treatment
is potentially curative
- Stage II – Advanced stage disease, that is, the tumor re-
sponse rate is low due to the aggressive behavior of the
cancer or the staging of the disease
- Stage III – No therapy to be offered, that is, there is no
effective therapeutic strategy and usually the treatment is
supportive (for instance, anti-hemorrhagic radiotherapy)
- Stage IV – Terminal, that is, the end stage disease leaving
the patient severely limited in his functions
2) Related to the nutritional status
- a – Nourished
Table 2: Classification of nutritional status:
Nourished At risk of malnutrition Malnourished
Stage I Ia Ib Ic
Stage II IIa IIb IIc
Stage III IIIa IIIb IIIc
Stage IV IVa IVb IVcNutrition Journal 2002, 1 http://www.nutritionj.com/content/1/1/1
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- b – At risk of malnutrition
- c – Malnourished
The nutritional assessment should be performed using the
Global Subjective Assessment or through the following
criteria:
- Nourished: absence of weight loss of more than 5% of
the usual body weight in the last 30 days
- At risk of malnutrition: weight loss of 5–10% of body
weight within the last 30 days
- Malnourished: weight loss of more than 10% within the
last 30 days
The patients should be further classified as shown in Table
2.
Nutrition support should be indicated based on the stage
of the oncologic process and the nutritional status. The
standard criteria for indication of nutrition support would
follow the scheme below:
Ia, IIa, IIIa, IVa  follow up (periodical nutritional assess-
ment)
Ib, IIb, IIIb, IVb  protein-caloric supplementation and/
or appetite stimulants
Ic, IIc, IIIc  nutritional therapy (enteral nutrition, total
parenteral nutrition, and peripheral parenteral nutrition)
IVc  enteral fluids / venous fluids (hydration)
Patients submitted to bone marrow transplantation and
those undergoing gastrointestinal surgery are not targeted
by these criteria. In both groups, nutrition support is indi-
cated in a routine basis.
Standard criteria to indicate nutrition support in cancer
patients should be implemented and QoL assessment is
an unconditional tool to determine the target population.
Therefore, nutrition support teams should consider QoL
benefits as an endpoint in further studies of the role of nu-
trition support in cancer.
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